KEZAR LIFE SCIENCES INC (KZR) Stock News

USA - Nasdaq - NASDAQ:KZR - US49372L2097 - Common Stock

6.24 USD

+0.09 (+1.46%)

Last: 12/3/2025, 8:00:03 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KZR Latest News, Press Relases and Analysis

All

Press Releases

22 days ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Third Quarter 2025 Financial Results

a month ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025

2 months ago - By: Benzinga

Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans

2 months ago - By: Stocktwits - Mentions: DFAS IWC WFC

Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive

4 months ago - By: The Motley Fool

Kezar Narrows Loss 37 Percent in Q2

a year ago - By: Benzinga

Looking Into Kezar Life Sciences's Recent Short Interest

2 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives

3 months ago - By: Zacks Investment Research

All You Need to Know About Kezar Life Sciences (KZR) Rating Upgrade to Buy

3 months ago - By: Kezar Life Sciences

Kezar Life Sciences to Participate in Two Upcoming Investor Conferences

4 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update

5 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis

6 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference

6 months ago - By: Yahoo Finance - Mentions: PRME EHC NVDA NPCE ...

Citi Downgrades Prime Medicine (PRME) to Neutral, Cuts PT to $1.50 Due to Market Uncertainty

6 months ago - By: Zacks Investment Research

Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?

7 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update

8 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results

8 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025

10 months ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update

a year ago - By: Glancy Prongay & Murray LLP

Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)

a year ago - By: Kezar Life Sciences

Kezar Life Sciences Announces 1-for-10 Reverse Stock Split

a year ago - By: Yahoo Finance

Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study

a year ago - By: Kezar Life Sciences

Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update

a year ago - By: Kezar Life Sciences, Inc.

Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal

a year ago - By: Yahoo Finance

FDA Put Brakes On Penny Stock Kezar Life Sciences' Mid-Stage Study For Lead Development Candidate After Patient Deaths

a year ago - By: Kezar Life Sciences, Inc.

Kezar Life Sciences Announces Clinical Hold of Zetomipzomib IND for Treatment of Lupus Nephritis